« Back to Record
Citation APA

Zeuzem, S., Bourgeois, S., Greenbloom, S., Buti, M., Aghemo, A., Lampertico, P., Janczewska, E., Lim, S. G., Moreno, C., Buggisch, P., Tam, E., Corbett, C., Willems, W., Vijgen, L., Fevery, B., Ouwerkerk-Mahadevan, S., Ackaert, O., Beumont, M., Kalmeijer, R., Sinha, R., & Biermer, M. (2019). JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology. doi:10.1002/hep.30527


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/286952

Zeuzem, S., Bourgeois, S., Greenbloom, S., Buti, M., Aghemo, A., Lampertico, P., Janczewska, E., Lim, S. G., Moreno, C., Buggisch, P., Tam, E., Corbett, C., Willems, W., Vijgen, L., Fevery, B., Ouwerkerk-Mahadevan, S., Ackaert, O., Beumont, M., Kalmeijer, R., Sinha, R., & Biermer, M. (2019). JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology. doi:10.1002/hep.30527